Dare Bioscience

Dare Bioscience Total Assets

The Total Assets of Dare Bioscience (DARE) as of Nov 2, 2026 is 32.47 M USD. In the previous year, Total Assets was 22.10 M USD — a change of 46.94% (higher).

Total Assets

32.47 MUSD

YoY

46.94%

Last updated:

Total Assets of Dare Bioscience is 2025 32.47 M USD. Total Assets of Dare Bioscience was 2024 22.10 M USD. It decreases by 46.94% higher compared to the previous year.

The Dare Bioscience Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
7.83 M USD
Jan 1, 2019
7.44 M USD
Jan 1, 2020
7.55 M USD
Jan 1, 2021
55.81 M USD
Jan 1, 2022
43.83 M USD
Jan 1, 2023
21.28 M USD
Jan 1, 2024
22.10 M USD
Jan 1, 2025
32.47 M USD
The Dare Bioscience Total Assets history
YEARTotal AssetsYoY
32.47 MUSD+46.94%
22.10 MUSD+3.85%
21.28 MUSD-51.44%
43.83 MUSD-21.47%
55.81 MUSD+639.10%
7.55 MUSD+1.45%
7.44 MUSD-4.91%
7.83 MUSD-45.11%
14.26 MUSD-62.16%
37.69 MUSD-51.82%
78.23 MUSD+46.51%
53.39 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Total Assets of Dare Bioscience is 32.47 M USD in 2025.

Total Assets of Dare Bioscience changed from 22.10 M USD to 32.47 M USD, representing a 46.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Dare Bioscience

All Key Metrics — Dare Bioscience